- The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. Paxton, J.W., Hardy, J.R., Evans, P.C., Harvey, V.J., Baguley, B.C. Cancer Chemother. Pharmacol. (1988)